International Hepatology

The Journal of Clinical Oncology features an important discussion led by Neil Newman MD MS, Colin Court, MD, PhD, and Alexander Parikh, MD, MPH on the best locoregional treatment strategies…

Alcohol use disorder remains a leading but preventable cause of morbidity and mortality worldwide, with profound implications for chronic liver disease. Yet, despite its significant burden, clinicians often face challenges…

In a significant advancement in cancer research, Dr. Zefei Jiang and his team from The Fifth Medical Center of  Chinese PLA General Hospital published the article "Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial" in Nature Medicine(IF=83) on January 1, 2024. This pivotal study investigates the efficacy and safety of combining toripalimab, an immune checkpoint inhibitor, with nab-paclitaxel in treating metastatic or recurrent triple-negative breast cancer (TNBC). TNBC, marked by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression, presents limited treatment options and a poor prognosis. The study addresses the urgent need for more effective therapies for this aggressive breast cancer subtype.

A recent post-hoc analysis of the PROSPER trial, published in JHEP Reports (2025), highlights the impact of pravastatin in reducing all-cause mortality in elderly patients at risk of liver fibrosis.The…

Professor Rohit Loomba played a pivotal role in a comprehensive network meta-analysis evaluating the efficacy of pharmacological therapies for fibrosis regression and MASH resolution. Published in Hepatology, this study analyzed…

Professor Jerome Boursier played a leading role in a multi-center study evaluating non-invasive tests (NITs) for fibrotic MASH, published in JHEP Reports. This study addresses a critical challenge in MASH…

A multi-center study across 13 centers in five countries evaluated the long-term outcomes of CARTO/PARTO for gastric variceal (GV) bleeding in 311 patients over 10 years.The results show excellent survival…

In January 2025, Scientific Reports published an observational pilot study evaluating the long-term efficacy and safety of entecavir (ETV) versus tenofovir alafenamide (TAF) in patients with chronic hepatitis B.Key Findings:After…